Literature DB >> 2429157

Quantitation of neutralization of interferon by antibody.

Y Kawade.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 2429157     DOI： 10.1016/0076-6879(86)19076-8

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  27 in total

1.  Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.

Authors:  Valentina Tomassini; Andrea Paolillo; Pierluigi Russo; Elisabetta Giugni; Luca Prosperini; Claudio Gasperini; Guido Antonelli; Stefano Bastianello; Carlo Pozzilli
Journal:  J Neurol       Date:  2005-09-14       Impact factor: 4.849

2.  Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.

Authors:  Francesca Gilli; Fabiana Marnetto; Guglielmo Stefanuto; Valentina Rinaldi; Federica Farinazzo; Simona Malucchi; Marco Capobianco; Marzia Caldano; Arianna Sala; Antonio Bertolotto
Journal:  Mol Diagn       Date:  2004

3.  Molecular and functional characterization of turkey interferon.

Authors:  M Suresh; K Karaca; D Foster; J M Sharma
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

4.  Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.

Authors:  D D Douglas; J Rakela; H J Lin; F B Hollinger; H F Taswell; A J Czaja; J B Gross; M L Anderson; K Parent; C R Fleming
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

5.  The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.

Authors:  D Paolicelli; M D'Onghia; F Pellegrini; V Direnzo; P Iaffaldano; V Lavolpe; M Trojano
Journal:  J Neurol       Date:  2013-02-17       Impact factor: 4.849

6.  Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

Authors:  A Bertolotto; S Malucchi; A Sala; G Orefice; P B Carrieri; M Capobianco; E Milano; F Melis; M T Giordana
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

7.  Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Authors:  A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

Review 8.  Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.

Authors:  Hans-P Hartung; Chris Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew Pachner; Huub Schellekens; Finn Sellebjerg; Krysztof Selmaj; Per Soelberg Sorensen
Journal:  J Neurol       Date:  2007-04-24       Impact factor: 4.849

9.  Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.

Authors:  X Lin; C R Tench; B Turner; L D Blumhardt; C S Constantinescu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

10.  Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.

Authors:  Emilia Sbardella; Valentina Tomassini; Claudio Gasperini; Francesca Bellomi; Luca Ausili Cefaro; Vincenzo Brescia Morra; Guido Antonelli; Carlo Pozzilli
Journal:  BMC Neurol       Date:  2009-10-13       Impact factor: 2.474
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.